Search Results

Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer.

• Authors : Janaththani P; Australian Prostate Cancer BioResource; Practical Consortium;

• Source: Research square [Res Sq] 2023 Oct 24. Date of Electronic Publication: 2023 Oct 24.Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: Res Sq Subsets: PubMed not

Record details

Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.

• Authors : Thomas PB; School of Biomedical Sciences at Translational Research Institute (TRI), Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD 4102, Australia.; Australian Prostate Cancer Research Centre-Queensland, Brisbane, QLD 4102, Australia.

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/genetics ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/metabolism

• Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Oct 24; Vol. 30 (11), pp. 9437-9447. Date of Electronic Publication: 2023 Oct 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729

Record details

hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.

• Authors : Adams MN; School of Biomedical Sciences, Faculty of Health, Translational Research Institute, Queensland University of Technology, Woolloongabba, Queensland, Australia.; Croft LV

Subjects: DNA-Binding Proteins*/DNA-Binding Proteins*/DNA-Binding Proteins*/metabolism ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/genetics

• Source: The Prostate [Prostate] 2023 May; Vol. 83 (7), pp. 628-640. Date of Electronic Publication: 2023 Feb 22.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Gene expression based inference of cancer drug sensitivity.

• Authors : Chawla S; Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, 110020, India.; Rockstroh A

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Melanoma*/Melanoma*/Melanoma*/drug therapy

• Source: Nature communications [Nat Commun] 2022 Sep 27; Vol. 13 (1), pp. 5680. Date of Electronic Publication: 2022 Sep 27.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Isomeric lipid signatures reveal compartmentalized fatty acid metabolism in cancer.

• Authors : Young RSE; School of Chemistry and Physics, Queensland University of Technology, Brisbane, Queensland, Australia; Central Analytical Research Facility (CARF), Queensland University of Technology, Brisbane, Queensland, Australia.

Subjects: Fatty Acids*/Fatty Acids*/Fatty Acids*/metabolism ; Neoplasms*; Glycerophospholipids/Glycerophospholipids/Glycerophospholipids/chemistry

• Source: Journal of lipid research [J Lipid Res] 2022 Jun; Vol. 63 (6), pp. 100223. Date of Electronic Publication: 2022 May 07.Publisher: Elsevier Country of Publication: United States NLM ID: 0376606 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.

• Authors : Tang YH; Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia.; Rockstroh A

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/metabolism ; Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/pathology; Animals

• Source: Breast cancer research : BCR [Breast Cancer Res] 2022 Jan 25; Vol. 24 (1), pp. 8. Date of Electronic Publication: 2022 Jan 25.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer.

• Authors : Bock N; School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia.; Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia.

Subjects: Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/pathology; Androgen Antagonists/Androgen Antagonists/Androgen Antagonists/pharmacology ; Androgen Antagonists/Androgen Antagonists/Androgen Antagonists/therapeutic use

• Source: Science advances [Sci Adv] 2021 Jun 30; Vol. 7 (27). Date of Electronic Publication: 2021 Jun 30 (Print Publication: 2021).Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Electronic-Print

Record details

Leptin antagonism inhibits prostate cancer xenograft growth and progression.

• Authors : Philp LK; Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Queensland, Australia.; Rockstroh A

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/metabolism ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/metabolism; Androgen Antagonists/Androgen Antagonists/Androgen Antagonists/therapeutic use

• Source: Endocrine-related cancer [Endocr Relat Cancer] 2021 Apr 29; Vol. 28 (5), pp. 353-375. Date of Electronic Publication: 2021 Apr 29.Publisher: BioScientifica Country of Publication: England NLM ID: 9436481 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-6821

Record details

Apocryphal FADS2 activity promotes fatty acid diversification in cancer.

• Authors : Young RSE; School of Chemistry and Physics, Queensland University of Technology, Brisbane, QLD 4000, Australia.; Bowman AP

Subjects: Signal Transduction*; Fatty Acid Desaturases/Fatty Acid Desaturases/Fatty Acid Desaturases/*metabolism ; Fatty Acids/Fatty Acids/Fatty Acids/*biosynthesis

• Source: Cell reports [Cell Rep] 2021 Feb 09; Vol. 34 (6), pp. 108738.Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247

Record details

The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.

• Authors : Thomas PB; Ghrelin Research Group, Translational Research Institute, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.; Comparative and Endocrine Biology Laboratory, Translational Research Institute, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

• Source: PeerJ [PeerJ] 2021 Feb 01; Vol. 9, pp. e10280. Date of Electronic Publication: 2021 Feb 01 (Print Publication: 2021).Publisher: PeerJ Inc Country of Publication: United States NLM ID: 101603425 Publication Model: eCollection Cited Medium: Print ISSN: 2167-8359

Record details